Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data

References

• Smith CM. Origin and uses of primum non nocere – above all, do no harm! J Clin Pharmacol. 2005;45(4):371–377.
   PubMed Web of Science ®Google Scholar
• Lu D, Lu T, Stroh M, et al. A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities. Cancer Chemother Pharmacol. 2016;77(3):459–476.
   PubMed Web of Science ®Google Scholar
• Ma J, Bao YP, Wang RJ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2018;24:1868–1883.
   PubMed Web of Science ®Google Scholar
• Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019;13(2):93–103.
   PubMed Web of Science ®Google Scholar
• Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend. 2014;144:1–11.
   PubMed Web of Science ®Google Scholar
• Nasser AF, Greenwald MK, Vince B, et al. Sustained-release buprenorphine (RBP-6000) nlocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder. J Clin Psychopharmacol. 2016;36(1):18–26.
   PubMed Web of Science ®Google Scholar
• Haight BR, Learned SM, Laffont CM, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;393(10173):778–790.
   PubMed Web of Science ®Google Scholar
• Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019;393(10182):1760–1772.
   PubMed Web of Science ®Google Scholar
• Pendergrass SA, Crist RC, Jones LK, et al. The importance of buprenorphine research in the opioid crisis. Mol Psychiatry. 2019;24(5):626–632.
   PubMed Web of Science ®Google Scholar
• Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018;178(6):764–773.
   PubMed Web of Science ®Google Scholar
• Schuh KJ, Johanson C-E. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend. 1999;56(1):55–60.
   PubMed Web of Science ®Google Scholar
• Compton PJ, Ling W, Moody D, et al. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend. 2006;82(1):25–31.
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry. 1978;35(4):501–516.
   PubMed Web of Science ®Google Scholar
• Mello NK, Mendelson JH, Kuehnle JC. Buprenorphine effects on human heroin self-administration: an operant analysis. J Pharmacol Exp Ther. 1982;223(1):30–39.
   PubMed Web of Science ®Google Scholar
• Mello NK, Mendelson JH. Buprenorphine suppresses heroin use by heroin addicts. Science. 1980;207(4431):657–659.
   PubMed Web of Science ®Google Scholar
• Bickel WK, Stitzer ML, Bigelow GE, et al. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther. 1988;247(1):47–53.
   PubMed Web of Science ®Google Scholar
• Rosen MI, Wallace EA, McMahon TJ, et al. Buprenorphine: duration of blockade of effects of intramuscular hydromorphone. Drug Alcohol Depend. 1994;35(2):141–149.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Bigelow GE, et al. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther. 1995;274(1):361–372.
   PubMed Web of Science ®Google Scholar
• Strain EC, Walsh SL, Preston KL, et al. The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology. 1997;129(4):329–338.
   PubMed Web of Science ®Google Scholar
• Schuh KJ, Walsh SL, Stitzer ML. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology. 1999;145(2):162–174.
   PubMed Web of Science ®Google Scholar
• Greenwald MK, Johanson CE, Schuster CR. Opioid reinforcement in heroin-dependent volunteers during outpatient buprenorphine maintenance. Drug Alcohol Depend. 1999;56(3):191–203.
   PubMed Web of Science ®Google Scholar
• Comer SD, Collins ED, Fischman MW. Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmacology. 2001;154(1):28–37.
   PubMed Web of Science ®Google Scholar
• Strain EC, Walsh SL, Bigelow GE. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology. 2002;159(2):161–166.
   PubMed Web of Science ®Google Scholar
• Greenwald MK, Schuh KJ, Hopper JA, et al. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology. 2002;160(4):344–352.
   PubMed Web of Science ®Google Scholar
• Greenwald MK, Johanson CE, Moody DE, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28(11):2000–2009.
   PubMed Web of Science ®Google Scholar
• Comer SD, Walker EA, Collins ED. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology. 2005;181(4):664–675.
   PubMed Web of Science ®Google Scholar
• Correia CJ, Walsh SL, Bigelow GE, et al. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. Psychopharmacology. 2006;189(3):297–306.
   PubMed Web of Science ®Google Scholar
• Greenwald M, Johanson CE, Bueller J, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry. 2007;61(1):101–110.
   PubMed Web of Science ®Google Scholar
• Ling W, Wesson DR, Charuvastra C, et al. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 1996;53(5):401–407.
   PubMed Web of Science ®Google Scholar
• Schottenfeld RS, Pakes JR, Oliveto A, et al. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997;54(8):713–720.
   PubMed Web of Science ®Google Scholar
• Fischer G, Gombas W, Eder H, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction. 1999;94(9):1337–1347.
   PubMed Web of Science ®Google Scholar
• Pani PP, Maremmani I, Pirastu R, et al. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000;60(1):39–50.
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Bridge TP, Herbert S, et al. Buprenorphine/Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–958.
   PubMed Web of Science ®Google Scholar
• Kakko J, Svanborg KD, Kreek MJ, et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662–668.
   PubMed Web of Science ®Google Scholar
• Marsch LA, Bickel WK, Badger GJ, et al. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing. Drug Alcohol Depend. 2005;77(2):195–204.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365–374.
   PubMed Web of Science ®Google Scholar
• Kakko J, Grönbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry. 2007;164(5):797–803.
   PubMed Web of Science ®Google Scholar
• Soyka M, Zingg C, Koller G, et al. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol. 2008;11(5):641–653.
   PubMed Web of Science ®Google Scholar
• Rosenthal RN, Ling W, Casadonte P, et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction. 2013;108(12):2141–2149.
   PubMed Web of Science ®Google Scholar
• Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79–87.
   PubMed Web of Science ®Google Scholar
• Gryczynski J, Mitchell SG, Jaffe JH, et al. Retention in methadone and buprenorphine treatment among African Americans. J Subst Abuse Treat. 2013;45(3):287–292.
   PubMed Web of Science ®Google Scholar
• Mitchell G, Gryczynski J, Schwartz RP, et al. A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans. Drug Alcohol Depend. 2013;128(3):222–229.
   PubMed Web of Science ®Google Scholar
• Hoffman K, Peyton ML, Sumner M. Safety of a rapidly dissolving buprenorphine/naloxone sublingual tablet (BUP-NLX-RDT) for treatment of opioid dependence: a multicenter, open-label extension study. J Addict Med. 2017;11(3):217–223.
   PubMed Web of Science ®Google Scholar
• Lee JD, Nunes E, Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–318.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Comer SD, Lofwall MR, et al. Effect of Buprenorphine weekly depot (CAM2038) and hydromorphone blockade in Individuals with opioid use disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74(9):894–902.
   PubMed Web of Science ®Google Scholar
• Timko C, Schultz NR, Cucciare MA, et al. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22–35.
   PubMed Web of Science ®Google Scholar
• Fareed A, Vayalapalli S, Casarella J, et al. Effect of buprenorphine dose on treatment outcome. J Addict Dis. 2012;31(1):8–18.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.
   PubMed Web of Science ®Google Scholar
• Gunderson EW, Hjelmström P, Sumner M. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial. Clin Ther. 2015;37(10):2244–2255.
   PubMed Web of Science ®Google Scholar
• Jacobs P, Ang A, Hillhouse MP, et al. Treatment in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories. Am J Addict. 2015;24(7):667–675.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Hanna N, Laurenzi P, et al. Multi-centre observational study of buprenorphine use in 32 Italian drug addiction centres. Drug Alcohol Depend. 2008;94(1–3):125–132.
   PubMed Web of Science ®Google Scholar
• Vigezzi P, Guglielmino L, Marzorati P, et al. Multimodal drug addiction treatment: a field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients. J Subst Abuse Treat. 2006;31(1):3–7.
   PubMed Web of Science ®Google Scholar
• Pinto H, Maskrey V, Swift L, et al. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 2010;39(4):340–352.
   PubMed Web of Science ®Google Scholar
• Apelt SM, Scherbaum N, Gölz J, et al. Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care. Pharmacopsychiatry. 2013;46:94–107.
   PubMed Web of Science ®Google Scholar
• Serre F, Fatseas M, Denis C, et al. Predictors of craving and substance use among patients with alcohol, tobacco, cannabis or opiate addictions: commonalities and specificities across substances. Addict Behav. 2018; 83:123–129.
   PubMed Web of Science ®Google Scholar
• Willenbring ML, Hagedorn HJ, Postier AC, et al. Variations in evidence-based clinical practices in nine United States Veterans Administration opioid agonist therapy clinics. Drug Alcohol Depend. 2004;75(1):97–106.
   PubMed Web of Science ®Google Scholar
• Trafton JA, Minkel J, Humphreys K. Determining effective methadone doses for individual opioid-dependent patients. PLoS Med. 2006;3(3):e80.
   PubMed Web of Science ®Google Scholar
• González-Saiz F, Rojas OL, Trujols J, et al. Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment. Drug Alcohol Depend. 2018;183:127–133.
   PubMed Web of Science ®Google Scholar
• Alcaraz S, González-Saiz F, Trujols J, et al. A cluster-analytic profiling of heroin-dependent patients based on level, clinical adequacy, and patient-desired adjustment of buprenorphine dosage during buprenorphine-naloxone maintenance treatment in sixteen Spanish centers.Drug Alcohol Depend. 2018;187:278–284.
   PubMed Web of Science ®Google Scholar